MK-2894 |
MK-2894 : Antagonist of PTGER4
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| PTGER4 |
|
|
Antagonist
up to 100 nM
Selectivity
In Vitro Selectivity Assessment
Potency Assay Off-Target:
MK-2894 exhibits exquisite selectivity against all other prostanoid receptors (>7000-fold) Ki: EP1 > ...
Potency Cellular
In Vitro
PTGER4
Mode of Action: Antagonist
Structure-Activity-Relationship data available? Yes
DOI Reference: 10.1021/jm901771h
In Vivo Validations
Mouse
Dose: 5 mg/Kg IV, 20 mg/Kg PO
Route of delivery:
Intravenous, oral
Plasma half life:
15 h
Systemic clearance:
23 mL/min/kg
Cmax:
1.4 uM
Bioavailability:
21%
Volume of Distribution at Steady-State:
7.6 L/Kg
DOI Reference: 10.1021/jm901771h
Rat
Dose: 5 mg/Kg IV, 20 mg/Kg
Route of delivery:
Intravenous, Oral
Plasma half life:
4.5 h
Systemic clearance:
9.2 mL/min/kg
Cmax:
4.5 uM
Bioavailability:
29%
Volume of Distribution at Steady-State:
2.6 L/Kk
DOI Reference: 10.1021/jm901771h
Dog
Dose: 1 mg/Kg IV, 5 mg/Kg PO
Route of delivery:
Intravenous, Oral
Plasma half life:
8.8 h
Systemic clearance:
3.2 mL/min/kg
Cmax:
3.3 uM
Bioavailability:
32%
Volume of Distribution at Steady-State:
0.91 L/Kg
DOI Reference: 10.1021/jm901771h
Monkey (Cynomolgus)
Dose: 1 mg/Kg IV, 5 mg/Kg PO
Route of delivery:
Intravenous, Oral
Plasma half life:
19 h
Systemic clearance:
0.91 mL/min/kg
Cmax:
0.05 uM
Bioavailability:
18%
Volume of Distribution at Steady-State:
7.9 L/Kg
DOI Reference: 10.1021/jm901771h
Chemical Information
| Molecular Formula | C25H22F3NO3S |
| SMILEs | Cc1sc(C)c(C(=O)NC2(c3ccc(C(=O)O)cc3)CC2)c1Cc1ccc(C(F)(F)F)cc1 |
| InChI | InChI=1S/C25H22F3NO3S/c1-14-20(13-16-3-7-19(8-4-16)25(26,27)28)21(15(2)33-14)22(30)29-24(11-12-24)18-9-5-17(6-10-18)23(31)32/h3-10H,11-13H2,1-2H3,(H,29,30)(H,31,32) |
| Molecular weight | 473.13 Da |
| AlogP | 0.0 |
| HBond acceptors | 4 |
| HBond donors | 2 |
| Atoms | 55 |
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.